IM Cannabis (IMCC)
(Delayed Data from NSDQ)
$0.46 USD
+0.01 (1.41%)
Updated Jun 14, 2024 03:56 PM ET
After-Market: $0.45 -0.01 (-2.26%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth F Momentum B VGM
Brokerage Reports
IM Cannabis Corp. [IMCC]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
4Q23 Results Tempered, Global Regulatory Tailwinds Inflect 2H24
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
3Q23 Tough, Premium Ops in Place Despite Israel Unknowns PT $1
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
Weekly ReHash: 2Q23 Week III U.S. Cannabis Earnings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
Weekly ReHash: U.S. Cannabis Earnings Week II
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
4Q22 Reset with a Clean Slate for 2023, PT to $1.50
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
3Q22 Refocused Resources in Premium Segment, Lower PT to $7
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
2Q22 Flat, Growth & Margin Initiatives Set Up 2H22, Lower PT to $3, Buy
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Cannabis Industry Update: 2Q22 Week II Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: IM Cannabis Corp.
Industry: Medical - Products
Company: IM Cannabis Corp.
Industry: Medical - Products
1Q22 Solid, Export & Integration Progress Leading to Profitability, PT $5
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: IM Cannabis Corp.
Industry: Medical - Products
Cannabis Earnings 1Q22: Week II Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department